The Use of Etonogestrel Contraceptive Implant as Treatment for Endometrial Hyperplasia Without Atypia: A Cohort Study

Launched by UNIVERSITY OF THE PHILIPPINES · Apr 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a contraceptive implant called etonogestrel (Implant NXT) as a possible treatment for a condition known as endometrial hyperplasia without atypia. This condition causes the lining of the uterus to become thicker than normal, which can lead to cancer in a small number of women. The goal of the study is to see if using this implant can help return the uterine lining to a normal thickness within 3 to 6 months. While other treatments are available, this is the first time researchers are looking specifically at the implant for this condition.

Women aged 18 and older, who are still having menstrual cycles, and have been diagnosed with endometrial hyperplasia without atypia may be eligible to participate in the trial. Participants in the study will receive the etonogestrel implant for 6 to 12 months and will be monitored to see how their condition improves. It's important to note that this study is not yet recruiting participants, but it offers a potential new option for women looking to treat this condition while keeping their uterus.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • women aged 18 years old to perimenopause who present with or without abnormal uterine bleeding and who have an endometrial biopsy result which shows endometrial hyperplasia without atypia
• • women willing to have the etonogestrel implant (Implant NXT) for the duration of treatment (6-12 months)
• • women who wish to retain their uterus
• Exclusion Criteria:
• • -